Weight loss drugs are set to become a disproportionate share of Lilly's business.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. Learn more about LLY stock here.

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The pharmaceutical company also announced a partnership with Walmart (WMT) to make GLP-1s more accessible to consumers.

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica medications for diabetes and weight loss.

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has revealed a plan to spend $1.2 billion to upgrade its plant in Carolina, Puerto Rico.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising full-year guidance.

Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic growth initiatives.

Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss medicines, in return for Medicare coverage of their products, Endpoints News reported on Tuesday.